The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, shares the six-year updated results of the CLL14 trial (NCT02242942) which compared fixed-duration venetoclax plus obinutuzumab (VenG) to chlorambucil plus obinutuzumab (ClbG) for patients with previously untreated chronic lymphocytic leukemia (CLL). Dr Al-Sawaf shares the positive long-term efficacy and safety results of fixed-duration VenG compared to chemoimmunotherapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
